Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.52 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.52 |
| ▸ | RPS6KB1 | P23443 | 17/20 | 0.43 |
| ▸ | AKT1 | P31749 | 10/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | AKT2 | P31751 | 3/20 | 0.35 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24377365 | 0.95 | QPCT (0.55) | QPCTQPCTLRPS6KB1AKT1PIK3CA | |
| SCHEMBL26629804 | 0.89 | QPCT (0.49) | QPCTQPCTLRPS6KB1AKT1PIK3CA | |
| SCHEMBL30611005 | 0.89 | QPCT (0.49) | QPCTQPCTLRPS6KB1AKT1PIK3CA | |
| SCHEMBL30610995 | 0.89 | QPCT (0.46) | QPCTQPCTLRPS6KB1AKT1AKT2 | |
| SCHEMBL26629848 | 0.89 | QPCT (0.46) | QPCTQPCTLRPS6KB1AKT1AKT2 | |
| SCHEMBL26742773 | 0.88 | QPCT (0.48) | QPCTQPCTLRPS6KB1AKT1AKT2 | |
| SCHEMBL26742581 | 0.88 | QPCT (0.48) | QPCTQPCTLRPS6KB1AKT1SLC9A1 | |
| SCHEMBL30610998 | 0.88 | QPCT (0.50) | QPCTQPCTLRPS6KB1AKT1PIK3CA | |
| SCHEMBL30610990 | 0.88 | QPCT (0.50) | QPCTQPCTLRPS6KB1AKT1PIK3CA | |
| SCHEMBL26629815 | 0.88 | QPCT (0.50) | QPCTQPCTLRPS6KB1AKT1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382891-A1 | GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF | BLACKSMITH MEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382891-A1 | GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF | BLACKSMITH MEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382891-A1 | GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF | BLACKSMITH MEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| WO-2022086920-A1 | GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF | BLACKSMITH MEDICINES, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022086920-A1 | GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF | BLACKSMITH MEDICINES, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382891-A1 | GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF | QPCT, QPCTL, GLUL | QPCT 1/4885QPCTL 2/4885RPS6KB1 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.